摘要目的 探讨XPD Asp312Asn单核酸多态性在预测以奥沙利铂为基础方案的转移结直肠癌患者化疗疗效的价值.方法 应用TaqMan荧光探针Real-Time PCR分析方法对106例接受奥沙利铂为基础方案(FOLFOX4方案72例,XELOX方案34例)化疗的转移结直肠癌患者进行着色性干皮病互补基团D(XPD) Asp312Asn基因型测定.Logistic回归分析疗效,Kaplan-Meier方法预测生存期.结果 106例结直肠癌患者化疗有效率为57.6％ (61/106),两种化疗方案中G/G、G/A和A/A基因型在化疗有效组和无效组之间分布的差异无统计学意义(P＞0.05).多因素生存分析显示A/A基因型、癌胚抗原(CEA)≥5 ng/ml和年龄≥65岁的患者生存时间相对较短,具有统计学意义(P＜0.05).结论 XPD Asp312Asn单核酸多态性可以作为转移结直肠癌患者生存期的一个预测指标,但与奥沙利铂药物敏感性的关联不大,需要进一步论证.

abstractsObjective This study was to determine the role of the Xeroderma pigmentosum group D (XPD) Asp312Asn polymorphism in predicting response to Oxaliplatin based chemotherapies and survival in patients with metastatic colorectal cancer.Methods This study enrolled a total of 106 patients treated with FOLFOX4 (n =72) or XELOX (n =34) regimen.The genotype of XPD Asp312Asn was analyzed by TaqMan probe based real-Time polymerase chain reaction (PCR).Logistic regression was used to predict the response to the treatments.Cox proportion hazards models and Kaplan-Meier method were applied to predict the survival.Results The effective rate of chemotherapy in 106 patients with colorectal cancer was 57.6％ (61/106).There was no significant difference in the distribution of G/G,G/A and A/A genotypes between the two groups (P ＞ 0.05).Multivariate survival analysis showed that the survival time of patients with A/A genotype,carcinoembryonic antigen (CEA) (＞5 ng/ml) and age (＞65 years) was relatively short,with statistical significance (P ＜ 0.05).Conclusions XPD Asp312Asn single nucleic acid polymorphism can be used as a predictor of survival in patients with metastatic colorectal cancer,but it is not associated with oxaliplatin sensitivity and needs further study.